TY  - JOUR
AU  - Joseph, Nuradh
AU  - Cicchetti, Alessandro
AU  - McWilliam, Alan
AU  - Webb, Adam
AU  - Seibold, Petra
AU  - Fiorino, Claudio
AU  - Cozzarini, Cesare
AU  - Veldeman, Liv
AU  - Bultijnck, Renée
AU  - Fonteyne, Valérie
AU  - Talbot, Christopher J
AU  - Symonds, Paul R
AU  - Johnson, Kerstie
AU  - Rattay, Tim
AU  - Lambrecht, Maarten
AU  - Haustermans, Karin
AU  - De Meerleer, Gert
AU  - Elliott, Rebecca M
AU  - Sperk, Elena
AU  - Herskind, Carsten
AU  - Veldwijk, Marlon
AU  - Avuzzi, Barbara
AU  - Giandini, Tommaso
AU  - Valdagni, Riccardo
AU  - Azria, David
AU  - Jacquet, Marie-Pierre Farcy
AU  - Charissoux, Marie
AU  - Vega, Ana
AU  - Aguado-Barrera, Miguel E
AU  - Gómez-Caamaño, Antonio
AU  - Franco, Pierfrancesco
AU  - Garibaldi, Elisabetta
AU  - Girelli, Giuseppe
AU  - Iotti, Cinzia
AU  - Vavassori, Vittotorio
AU  - Chang-Claude, Jenny
AU  - West, Catharine M L
AU  - Rancati, Tiziana
AU  - Choudhury, Ananya
TI  - High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer.
JO  - Frontiers in oncology
VL  - 12
SN  - 2234-943X
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2022-02854
SP  - 937934
PY  - 2022
AB  - We hypothesized that increasing the pelvic integral dose (ID) and a higher dose per fraction correlate with worsening fatigue and functional outcomes in localized prostate cancer (PCa) patients treated with external beam radiotherapy (EBRT).The study design was a retrospective analysis of two prospective observational cohorts, REQUITE (development, n=543) and DUE-01 (validation, n=228). Data were available for comorbidities, medication, androgen deprivation therapy, previous surgeries, smoking, age, and body mass index. The ID was calculated as the product of the mean body dose and body volume. The weekly ID accounted for differences in fractionation. The worsening (end of radiotherapy versus baseline) of European Organisation for Research and Treatment of Cancer EORTC) Quality of Life Questionnaire (QLQ)-C30 scores in physical/role/social functioning and fatigue symptom scales were evaluated, and two outcome measures were defined as worsening in ≥2 (WS2) or ≥3 (WS3) scales, respectively. The weekly ID and clinical risk factors were tested in multivariable logistic regression analysis.In REQUITE, WS2 was seen in 28
KW  - fatigue (Other)
KW  - functional loss (Other)
KW  - integral dose (Other)
KW  - prostate cancer (Other)
KW  - radiotherapy - adverse effects (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36387203
C2  - pmc:PMC9645430
DO  - DOI:10.3389/fonc.2022.937934
UR  - https://inrepo02.dkfz.de/record/182686
ER  -